The cellular response depended on the assay context. At 10 µM, GBR12909 shifted dopamine potency significantly in U2OS-DAT cells; the corresponding shift in JumpIn-DAT cells did not reach significance (p = 0.057). Inhibitor-only, transporter-expression and receptor-antagonist controls supported interpretation of the impedance response. [1]
Vanoxerine dihydrochloride also altered human cardiac model electrophysiology. Microtissues showed delayed repolarization and EAD-like events during spontaneous activity; events were absent with 1.5 Hz pacing. A second cardiomyocyte MEA model showed repolarization delays and EAD-like events, although the 100 nM, 1 Hz repolarization comparison had p = 0.0502. Substantial platform drug loss and differing model conditions limit concentration comparisons. [2]
Functional DAT inhibition in U2OS-DAT cells
Cell-based study · U2OS cells transiently expressing human DAT; endogenous D1-receptor impedance readout [1]
GBR12909 enhanced dopamine-dependent impedance responses. Mock transfection and D1-receptor antagonist controls support the transport-dependent interpretation. This is an indirect functional assay, not a direct dopamine-flux or binding-affinity measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 pM–10 µM for inhibitor curve; 10 µM for dopamine-response comparison
- Exposure duration
- 60 min pretreatment; 120 min after dopamine addition
- Method
- xCELLigence; net area under the impedance curve; fixed pseudo-Hill slope of 1
- Vehicle
- 0.1% DMSO in PBS; dopamine vehicle contained 1 mM ascorbic acid in PBS
- Co-treatment
- Dopamine 3.16 µM for inhibitor potency; dopamine concentration-response experiment also evaluated
Methods and source locations
Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: GBR12909
Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.
Methods Chemicals and reagents; Cell pretreatment/stimulation; Results Figures 1–2 and Table 1; SI Figures S1–S2
Apparent inhibition of DAT via dopamine-dependent impedance: Pretreatment with increasing GBR12909 followed by 3.16 µM dopamine; AUC over 120 min — Table 1, U2OS-DAT GBR12909 + 3.16 µM dopamine row; Figure 2c–d
Dopamine apparent potency with versus without 10 µM GBR12909: Dopamine concentration-response; fixed pseudo-Hill slope 1 — Table 1; Figure 2a–b; Results DAT inhibition restores apparent potency
Functional DAT inhibition in inducible JumpIn-DAT cells
Cell-based study · HEK293 JumpIn-DAT cells induced with 1 µg/mL doxycycline; alpha-2 adrenergic receptor-dependent impedance readout [1]
Concentration-dependent enhancement of dopamine response gave an apparent inhibitor potency. The dopamine-potency shift with fixed 10 µM GBR12909 did not reach statistical significance (p = 0.057). Doxycycline-negative cells and receptor antagonists were controls; GBR12909 alone did not substantially change pretreatment impedance.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 pM–10 µM for inhibitor curve; 10 µM for dopamine-response comparison
- Exposure duration
- 60 min pretreatment; 30 min after dopamine addition
- Method
- xCELLigence; net AUC; fixed pseudo-Hill slope 1
- Vehicle
- 0.1% DMSO in PBS; dopamine vehicle contained 1 mM ascorbic acid in PBS
- Co-treatment
- Dopamine 10 µM for inhibitor potency; cocaine was a separate comparator, not a co-treatment
Methods and source locations
Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: GBR12909
Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.
Methods; Results Figures 4–5 and Table 1; SI Figures S1–S2
Apparent inhibition of DAT via dopamine-dependent impedance: Increasing inhibitor followed by 10 µM dopamine; AUC over 30 min — Table 1, JumpIn-DAT +dox GBR12909 + 10 µM dopamine row; Figure 5c–d
Dopamine apparent potency with versus without 10 µM GBR12909: Dopamine concentration-response comparison — Table 1; Figure 5a–b; Results Characterization of DAT inhibitors
Repolarization and pacing-dependent events in human cardiac microtissues
Cell-based study · WTC11-GCaMP6f hiPSC-derived complex cardiac microphysiological system [2]
Vanoxerine delayed repolarization and produced early-afterdepolarization-like events during spontaneous activity. Events were absent at 1.5 Hz pacing despite repolarization prolongation. Cell-free exposure analysis found 99% drug loss in the platform; nominal concentrations must not be equated to measured free tissue exposure.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 10, 30 and 100 nM nominal, escalating
- Exposure duration
- 30 min incubation at each concentration before acquisition (Methods 2.4)
- Method
- Optical voltage, calcium and contractility readouts; spontaneous and paced conditions
- Vehicle
- 0.1% DMSO in maturation medium
- Co-treatment
- None; sotalol and dofetilide were separate positive-control experiments
- Reported limits
- Discussion 4.3 describes acute exposures as approximately 35 min per concentration; Methods specifies 30 min incubation. Actual tissue drug exposure was not established by cell-free effluent loss.
Methods and source locations
Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: Vanoxerine
Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.
Methods 2.1–2.6, 2.8–2.9; Results 3.1–3.4; Tables 1–2; Figure 3; SI Tables S1 and S3
Spontaneous voltage-readout EAD-like event incidence: Voltage-sensitive optical readout; N = 4 as reported. Independent donor/batch count is not specified for this condition. — Table 1 Observed EADs (Voltage); SI Table S3 p. 9 including vehicle
EAD-like events with 1.5 Hz pacing: Pacing-rate comparison; no exact graph amplitudes extracted — Results 3.2; Figure 3 and caption
Nonspecific vanoxerine loss in cell-free MPS: LC-MS/MS; effluent compared with unperfused control solution — Methods 2.8; Results 3.4; Table 2
Electrophysiological effects in human iPSC-derived cardiomyocytes
Cell-based study · Commercial iCell Cardiomyocytes2 on multielectrode arrays; spontaneous, 1 Hz and 1.5 Hz conditions [2]
Vanoxerine delayed repolarization and produced EAD-like events in this second cardiac model. At 100 nM and 1 Hz the repolarization comparison had p = 0.0502, outside the study p < 0.05 threshold. The model differed from the microfluidic system in cell source, media, exposure and platform; direct quantitative comparison is not justified.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.3–100 nM nominal
- Exposure duration
- 1 h after compound application
- Method
- MEA field potentials; double-delta FPD corrected by baseline and plate/timepoint vehicle controls
- Vehicle
- Final DMSO did not exceed 0.1%; serum-free FluoroBrite DMEM
- Co-treatment
- None
- Reported limits
- Model-specific free exposure was not measured; Figure 5 sample counts vary by condition. LEAP traces are qualitative, with n = 1–2 in Table S5.
Methods and source locations
Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: Vanoxerine
Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.
Methods 2.7 and 2.9; Results 3.5; Figure 5; SI Tables S4–S5
EAD-like events in hiPSC-CM MEA recordings: MEA field potential readout; event incidence is not an IC50 — Results 3.5; Figure 5A–B and caption
Repolarization prolongation at 100 nM, 1 Hz versus vehicle: Double-delta field potential duration; no exact graph amplitude extracted — Results 3.5 parenthetical comparison; Figure 5B